

<b><u>CONTENTS</u></b>		
	<b>CHAPTER-1</b> <b>New Analytical Methods for Drug Analysis</b>	<b>1-59</b>
1.1	General Introduction	<b>1</b>
1.1.1	Organic Synthetic Drugs	<b>2</b>
1.1.2	Pharmacopoeias to Ensure the Safety of Drugs	<b>3</b>
1.1.3	Analytical Techniques for Drugs	<b>3</b>
1.1.4	Titrimetric Methods	<b>4</b>
1.1.5	Chromatography	<b>18</b>
1.2	HPLC: High Performance Liquid Chromatography	<b>22</b>
1.2.1	Introduction	<b>22</b>
1.2.2	Mobile Phase Reservoir, filtering	<b>24</b>
1.2.3	Pump	<b>24</b>
1.2.4	Injector	<b>26</b>
1.2.5	Column	<b>26</b>
1.2.6	Detector	<b>28</b>
1.2.7	Data System	<b>29</b>
1.3	Liquid Chromatography-Mass Spectrometry (LCMS)	<b>29</b>
1.3.1	Introduction	<b>29</b>
1.3.2	Adapting L C Methods	<b>30</b>
1.3.3	Instrumentation	<b>31</b>
1.3.4	Ionization Methods	<b>31</b>
1.3.5	Nebulization and De Solvation	<b>34</b>
1.3.6	Collision Induced Dissociation and Multiple Stage MS	<b>38</b>
1.3.7	Applications	<b>41</b>
1.4	HPLC Method Development	<b>44</b>
1.4.1	Systematic Approach for Chromatographic Separation of Pharmaceutical Compounds	<b>46</b>

1.4.2	The Column and Flow Rate	46
1.4.3	The Mobile Phase	46
1.4.4	Separation Temperature	47
1.4.5	Equilibrium of the Column with the Mobile Phase	47
1.5	Analytical Parameters Used in Assay Validation as per ICH Guidelines	48
1.5.1	Key Parameters of the Analytical Method Validation	48
1.5.2	Accuracy	48
1.5.3	Precision	49
1.5.4	Determination of Repeatability	49
1.5.5	Determination of Reproducibility	50
1.5.6	Linearity and Range	50
1.5.7	Limit of Detection	50
1.5.8	Limit of Quantitation	51
1.5.9	Selectivity and Specificity	51
1.5.10	Robustness	52
1.5.11	Ruggedness	52
1.5.12	Stability and System Suitability Tests	52
1.5.13	System Suitability Testing	52
1.6	References	56
	<b>Chapter 2</b> <b>Simultaneous Analysis of Metronidazole and Diloxanide Furoate in Human Plasma (In-vivo) by LCMS-MS</b>	<b>60-98</b>
2.1	Introduction	61
2.1.1	Metronidazole	61
2.1.2	Diloxanide Furoate	62
2.2	Review of literature	69
2.3	Materials and Methods	74
2.3.1	Instrumentation	74
2.3.2	Chemicals and Standard Drugs	74

---

2.3.3	Preparation of Solutions	74
2.4	Method Development	78
2.5	Method Validation	83
2.5.1	Selectivity	83
2.5.2	Linearity	83
2.5.3	Precision and Accuracy	85
2.5.4	Recovery	87
2.5.5	Stability of the Drug in Solution	89
2.6	Discussion of the Results	93
2.7	Conclusion	95
2.8	References	96
	<b>Chapter 3</b>	<b>99-</b>
	<b>LCMS- MS Method for the Simultaneous Analysis of Telmisartan and Hydrochlorothiazide in Human Plasma (In-vivo)</b>	<b>141</b>
3.1	Introduction	100
3.1.1	Telmisartan	100
3.1.2	Hydrochlorothiazide	101
3.2	Review of Literature	105
3.3	Materials and Methods	116
3.3.1	Instrumentation	116
3.3.2	Chemicals and Standard Drugs	116
3.3.3	Preparation of Solutions	116
3.4	Method Development	120
3.5	Method Validation	125
3.5.1	Selectivity	125
3.5.2	Linearity	125
3.5.3	Precision and Accuracy	126
3.5.4	Recovery	128
3.5.5	Stability of the Drug in Solution	130
3.6	Discussion of the Results	134

---

---

3.7	Conclusion	136
3.8	References	137
	<b>Chapter 4</b> <b>LCMS- MS Method for the Simultaneous Analysis of Metformin and Glibenclamide in Human Plasma (In-vivo)</b>	<b>142-180</b>
4.1	Introduction	143
4.1.1	Metformin	145
4.1.2	Glibenclamide	147
4.2	Review of Literature	153
4.3	Materials and Methods	153
4.3.1	Instrumentation	153
4.3.2	Chemicals and Standard Drugs	153
4.3.3	Preparation of Solutions	153
4.4	Method Development	157
4.5	Method Validation	162
4.5.1	Selectivity	162
4.5.2	Linearity	162
4.5.3	Precision and Accuracy	64
4.5.4	Recovery	167
4.5.5	Stability of the Drug in Solution	170
4.6	Discussion of the Results	175
4.7	Conclusion	176
4.8	References	177
	<b>Chapter 5</b> <b>RP HPLC Method Development and Validation for Simultaneous Estimation of Metronidazole and Diloxanide Furoate in Formulation Dosage Forms</b>	<b>181-195</b>
5.1	Introduction	182
5.2	Literature Review	182
5.3	Materials and Methods	182

---

5.3.1	Chemicals and Solvents	182
5.3.2	Instrumentation	182
5.3.3	Chromatographic Conditions	182
5.3.4	Preparation of Standard Solutions	182
5.3.5	Preparation of Sample Solutions	183
5.4	Method Development	183
5.5	Method Validation	184
5.5.1	System Suitability Parameters	186
5.5.2	Specificity	186
5.5.3	Linearity	186
5.5.4	Precision	188
5.5.5	Recovery	189
5.5.6	Robustness	191
5.5.7	Ruggedness	191
5.5.8	LOQ and LOD	192
5.5.9	Estimation of Drugs in Pharmaceutical Formulations	193
5.6	Discussion of the Results	193
5.7	Conclusion	195
5.8	References	195
	<b>Chapter 6</b> <b>RP HPLC Method Development and Validation for Simultaneous</b> <b>Estimation of Telmisartan and Hydrochlorothiazide in</b> <b>Formulation Dosage Forms</b>	<b>196-</b> <b>212</b>
6.1	Introduction	196
6.2	Literature Review	196
6.3	Materials and Methods	196
6.3.1	Chemicals and Solvents	196
6.3.2	Instrumentation	196
6.3.3	Chromatographic Conditions	198
6.3.4	Preparation of Standard Stock Solutions	198

6.3.5	Tablet Formulation	198
6.4	Optimization of HPLC Method	199
6.5	Method Validation	202
6.5.1	System Suitability Parameters	202
6.5.2	Specificity	203
6.5.3	Linearity	203
6.5.4	Precision	203
6.5.5	Robustness	205
6.5.6	Accuracy	206
6.5.7	Ruggedness	207
6.5.8	Limit of Detection and Limit of Quantization	208
6.5.9	Analysis of a Marketed Formulation	209
6.6	Results and Discussion	210
6.7	Conclusion	212
6.8	References	212
	<b>Chapter 7</b> <b>RP HPLC Method Development and Validation for Simultaneous Estimation of Metformin and Glibenclamide in Formulation Dosage Forms</b>	<b>213-229</b>
7.1	Introduction	214
7.2	Literature review	214
7.3	Materials and Methods	214
7.3.1	Chemicals and Solvents	214
7.3.2	Instrumentation	214
7.3.3	Experimental Conditions	214
7.3.4	Preparation of Standard Stock Solution	215
7.3.5	Preparation of Tablet Assay Solutions	215
7.4	Method Development	215
7.5	Method Validation	218
7.5.1	System Suitability	218

---

7.5.2	Specificity	218
7.5.3	Linearity	219
7.5.4	Precision	221
7.5.5	Recovery	221
7.5.6	Robustness	223
7.5.7	Ruggedness	224
7.5.8	LOD and LOQ	224
7.5.9	Assay of Tablet Formulation	225
7.6	Discussion of the Results	226
7.7	Conclusion	229
7.8	References	229
	<b>Chapter 8</b> <b>Development and Validation of New Analytical Methods for the Estimation of Chemotherapeutic Drugs by using RP-HPLC (Oxaliplatin, Capecitabine, Carboplatin and Gemcitabine)</b>	<b>230-292</b>
8.1	Introduction	231
8.1.1	Oxaliplatin	231
8.1.2	Capecitabine	233
8.1.3	Carboplatin	235
8.1.4	Introduction to Gemcitabine	238
8.2	Review of Literature	242
8.2.1	Review of Literature for oxaliplatin	242
8.2.2	Review of Literature for Capecitabine	246
8.2.3	Review of Literature for Carboplatin	251
8.2.4	Review of Literature for Gemcitabine	256
8.3	Materials and Methods	260
8.3.1	Instrumentation	260
8.3.2	Chemicals and Solvents	260
8.3.3	Preparation of the Drug Solutions	260
8.3.4	Preparation of Marketed Formulation Solution	260

---

8.4	Method Development	261
8.4.1	Method Development for Oxaliplatin	261
8.4.2	Method Development for Capecitabine	262
8.4.3	Method Development for Carboplatin	263
8.4.4	Method Development for Gemcitabine	263
8.5	Method Validation	269
8.5.1	System Suitability	269
8.5.2	Specificity	269
8.5.3	Linearity and Range	272
8.5.4	Accuracy	273
8.5.5	Precision	275
8.5.6	Ruggedness	276
8.5.7	Robustness	277
8.5.8	Limit of Detection and Limit of Quantization	278
8.5.9	Formulation Analysis	279
8.6	Discussions of the Results	282
8.7	References	286
	<b>Chapter 9</b> <b>Development and Validation of New Analytical Methods for the Estimation of Different Drugs by using RP-HPLC (Carvedilol, Venlafaxine, Thalidomide and Tenofovir)</b>	<b>293-350</b>
9.1	Introduction	294
9.1.1	Introduction to Carvedilol	294
9.1.2	Introduction to Venlafaxine	295
9.1.3	Introduction to Thalidomide	297
9.1.4	Introduction to Tenofovir	299
9.2	Review of Literature	303
9.2.1	Literature Review for Carvedilol	303
9.2.2	Literature Review for Venlafaxine	304
9.2.3	Literature Review for Thalidomide	307



9.2.4	Literature Review for Tenofovir	<b>309</b>
9.3	Materials and Methods	<b>318</b>
9.3.1	Instrumentation	<b>318</b>
9.3.2	Chemicals and Solvents	<b>318</b>
9.3.3	Preparation of the Drug Solutions	<b>318</b>
9.3.4	Preparation of Marketed Formulation Solution	<b>319</b>
9.4	Method Development	<b>320</b>
9.4.1	Method Development for Carvedilol	<b>320</b>
9.4.2	Method Development for Venlafaxine	<b>320</b>
9.4.3	Method Development for Thalidomide	<b>321</b>
9.4.4	Method Development for Tenofovir	<b>322</b>
9.5	Method Validation	<b>328</b>
9.5.1	System Suitability	<b>328</b>
9.5.2	Specificity	<b>328</b>
9.5.3	Linearity	<b>329</b>
9.5.4	Accuracy	<b>331</b>
9.5.5	Precision	<b>333</b>
9.5.6	Robustness	<b>335</b>
9.5.7	Ruggedness	<b>335</b>
9.5.8	Limit of Detection and Limit of Quantitation	<b>336</b>
9.5.9	Formulation Analysis	<b>336</b>
9.6	Discussion of the Results	<b>340</b>
9.7	References	<b>344</b>

<b><u>LIST OF TABLES</u></b>		
<b>Table no.</b>	<b>Name of the Table</b>	<b>P. no.</b>
Table 1.1	Degrees of freedom for poly atomic molecules	<b>10</b>
Table 1.2	Relative abundances of atoms and their natural isotopes	<b>15</b>
Table 2.1	Properties of Metronidazole	63
Table 2.2	Commercial Formulations of Metronidazole	63
Table 2.3	Properties of Diloxanide Furoate	64
Table 2.4	Commercial Formulations of Metronidazole	64
Table 2.5	Preparation of plasma spiked calibration curve dilutions for Metronidazole	76
Table 2.6	Preparation of plasma spiked calibration curve dilutions for Diloxanide Furoate	77
Table 2.7	Optimized chromatographic and mass parameters	79
Table 2.8	Plasma spiked calibration curve	84
Table 2.9	Precision at HQC and MQC levels	86
Table 2.10	Precision at LQC and LLOQC levels	87
Table 2.11	Recovery of Metronidazole	88
Table 2.12	Recovery of Diloxanide Furoate	88
Table 2.13	Showing the short term stability results.	90
Table 2.14	Long term stability results for Metronidazole and Diloxanide Furoate	90
Table 2.15	Freeze Thaw Stability results for Metronidazole and Diloxanide Furoate	91
Table 2.16	Bench-top stability results for Metronidazole and Diloxanide Furoate	92
Table 2.17	Auto-sampler stability results for Metronidazole and Diloxanide Furoate	92
Table 3.1	Properties of Telmisartan	103
Table 3.2	Properties of Hydrochlorothiazide	103

Table: 3.3	Telmisartan formulation composition	103
Table: 3.4	Hydrochlorothiazide formulation composition	104
Table: 3.5	Telmisartan Hydrochlorothiazide combination formulation	104
Table 3.6	Preparation of aqueous calibration curve dilutions for Telmisartan	118
Table 3.7	Preparation of aqueous calibration curve dilutions for Hydrochlorothiazide	118
Table 3.8	Preparation of plasma spiked calibration curve dilutions for Telmisartan	119
Table 3.9	Preparation of plasma spiked calibration curve dilutions for Hydrochlorothiazide	120
Table 3.10	Optimized chromatographic conditions	121
Table 3.11	Plasma spiked calibration curve	125
Table 3.12	Precision at HQC and LQC levels	127
Table 3.13	Precision at LQC and LLOQC levels	128
Table 3.14	Recovery of Telmisartan	129
Table 3.15	Recovery of Hydrochlorothiazide	129
Table 3.16	Showing the short term stability results.	130
Table 3.17	Long term stability results for Telmisartan and Hydrochlorothiazide	131
Table 3.18	Freeze Thaw Stability results for Telmisartan and Hydrochlorothiazide	132
Table 3.19	Bench-top stability results for Telmisartan and Hydrochlorothiazide	132
Table 3.20	Auto-sampler stability results for Telmisartan and Hydrochlorothiazide	133
Table 4.1	Preparation of aqueous calibration curve dilutions for Metformin	155
Table 4.2	Preparation of aqueous calibration curve dilutions for Glibenclamide	155
Table 4.3	Preparation of plasma spiked calibration curve dilutions for Metformin	156
Table4.4	Preparation of plasma spiked calibration curve dilutions for Glibenclamide	156

Table 4.5	Optimized chromatographic conditions	158
Table4.6	Plasma spiked calibration curve for Metformin and Glibenclamide	163
Table 4.7	Precision at HQC and LQC levels	165
Table 4.8	Precision at LQC and LLOQC levels	166
Table 4.9	Recovery of Metformin	168
Table 4.10	Recovery of Glibenclamide	169
Table 4.11	Short term stability results for Metformin and Glibenclamide	170
Table 4.12	Long term stability results for Metformin and Glibenclamide	171
Table 4.13	Freeze Thaw Stability results for Metformin and Glibenclamide	172
Table4.14	Bench-top stability results for Metformin and Glibenclamide	173
Table 4.15	Auto-sampler stability results for Metformin and Glibenclamide	174
Table 5.1	Optimized chromatographic conditions for the estimation of Metronidazole and Diloxanide Furoate	184
Table 5.2	Table showing Linearity results	187
Table 5.3	Table showing Intraday Precision results	189
Table 5.4	Table showing Interday Precision results	189
Table 5.5	Table showing recovery results of Diloxanide Furoate	190
Table 5.6	Table showing recovery results of Metronidazole	190
Table 5.7	Table showing robustness results of Diloxanide Furoate and Metronidazole	191
Table 5.8	Ruggedness results of Diloxanide Furoate and Metronidazole	192
Table 5.9	Table showing sensitivity results of Diloxanide Furoate and Metronidazole	192

Table 5.10	Table showing sensitivity results of Diloxanide Furoate and Metronidazole	193
Table 5.11	Summary results of Diloxanide Furoate and Metronidazole	194
Table: 6.1	Optimized method conditions	200
Table 6.2	Linearity results	204
Table 6.3	Results of Precision	205
Table 6.4	Robustness results	206
Table 6.5	Accuracy results	207
Table 6.6	Ruggedness results	208
Table 6.7	Results of LOD and LOQ	208
Table 6.8	Formulation assay results	209
Table 6.9	summary results for Telmisartan and Hydrochlorothiazide	211
Table 7.1	Table showing optimized condition for determination of Metformin and Glibenclamide.	216
Table 7.2	Table showing linearity results	219
Table 7.3	Precision results of Metformin and Glibenclamide	221
Table 7.4	Recovery results of Metformin	222
Table 7.5	Recovery results of Glibenclamide	222
Table 7.6	Robustness results of Metformin and Glibenclamide	223
Table 7.7	Ruggedness results of Metformin and Glibenclamide	224
Table 7.8	Results of LOD and LOQ	224
Table 7.9	Table showing Formulation results	225
Table 7.10	Summary results for Metformin and Glibenclamide	228

Table 8.1	Properties of Oxaliplatin	232
Table 8.2	List of brand names for Oxaliplatin	232
Table 8.3	Properties of Oxaliplatin	234
Table 8.4	Commercial Formulations of Capecitabine	234
Table 8.5	Properties of Carboplatin	236
Table 8.6	Commercial Formulations of Carboplatin	237
Table 8.7	Properties of Gemcitabine	240
Table 8.8	Commercial Formulations of Gemcitabine	241
Table 8.9	Optimized chromatographic conditions	264
Table 8.10	System Suitability Conditions	269
Table 8.11	Linearity results for the proposed methods	272
Table 8.12	Recovery Results for Oxaliplatin	273
Table 8.13	Recovery Results for Capecitabine	274
Table 8.14	Recovery Results for Carboplatin	274
Table 8.15	Recovery Results for Gemcitabine	275
Table 8.16	Precision Results for the developed methods	276
Table 8.17	Ruggedness Results for the developed methods	277
Table 8.18	Robustness Results for the developed methods	278
Table:8.19	Formulation Results for the drugs in the study	279
Table 8.20	Summary results for the estimation of Oxaliplatin, Capecitabine and Carboplatin	285
Table 9.1	Properties of Carvedilol	295
Table 9.2	Commercial Formulations of Carvedilol	295

---

Table 9.3	Properties of Venlafaxine	297
Table 9.4	List of brand names of Venlafaxine	297
Table 9.5	Properties of Thalidomide	299
Table 9.6	Commercial Formulations of Thalidomide	299
Table 9.7	Properties of Tenofovir	302
Table 9.8	Commercial Formulations of Tenofovir	302
Table 9.9	Optimized chromatographic conditions for the proposed methods	323
Table 9.10	System suitability results for the developed methods.	328
Table 9.11	Specificity results in the method under the study	329
Table 9.12	Linearity results for the proposed methods	330
Table 9.13	Recovery Results for Carvedilol	332
Table 9.14	Recovery Results for Venlafaxine	332
Table 9.15	Recovery Results for Thalidomide	332
Table 9.16	Recovery Results for Tenofovir	333
Table 9.17	Precision Results for the proposed methods	334
Table 9.18	Robustness Results for the proposed methods	334
Table 9.19	Ruggedness Results for the proposed methods	335
Table 9.20	Formulation results for the drugs in the study	337
Table 9.21	Summary results for the proposed methods in the study	343

## LIST OF FIGURES

Figure no.	Name of the Figure	Page no.
	<b>CHAPTER-1</b> <b>New Analytical Methods for Drug Analysis</b>	<b>1</b>
Figure 1.A	Applications of Analytical techniques	<b>3</b>
Figure 1.B	The Electromagnetic spectrum	<b>6</b>
Figure 1.C	The electromagnetic spectrum	<b>7</b>
Figure 1.D	Stretching vibrations	<b>9</b>
Figure 1.E	Bending Vibrations (ip: in plane; oop: out of plane)	<b>9</b>
Figure 1.F	Schematic block diagram of an MS equipment	<b>11</b>
Figure 1.G	The EI ion source	<b>12</b>
Figure 1.H	Fragmentation of the molecular ion	<b>13</b>
Figure 1.I	A mass spectrum and fragmentation	<b>13</b>
Figure 1.J	s-cleavage	<b>16</b>
Figure 1.K	a-cleavage	<b>17</b>
Figure 1.L	allylic-, benzylic-cleavage	<b>18</b>
Figure 1.M	Schematic presentation of a chromatographic system with partition of analyte A between the phases; $v$ mobile phase velocity	<b>19</b>
Figure 1.N	HPLC Instrumentation	<b>24</b>
Figure 1.O	HPLC Pump	<b>25</b>
Figure 1.P	HPLC Chromatogram	<b>28</b>



## LIST OF FIGURES

Figure no.	Name of the Figure	Page no.
	<b>CHAPTER-1</b> <b>New Analytical Methods for Drug Analysis</b>	<b>1</b>
Figure 1.A	Applications of Analytical techniques	<b>3</b>
Figure 1.B	The Electromagnetic spectrum	<b>6</b>
Figure 1.C	The electromagnetic spectrum	<b>7</b>
Figure 1.D	Stretching vibrations	<b>9</b>
Figure 1.E	Bending Vibrations (ip: in plane; oop: out of plane)	<b>9</b>
Figure 1.F	Schematic block diagram of an MS equipment	<b>11</b>
Figure 1.G	The EI ion source	<b>12</b>
Figure 1.H	Fragmentation of the molecular ion	<b>13</b>
Figure 1.I	A mass spectrum and fragmentation	<b>13</b>
Figure 1.J	s-cleavage	<b>16</b>
Figure 1.K	a-cleavage	<b>17</b>
Figure 1.L	allylic-, benzylic-cleavage	<b>18</b>
Figure 1.M	Schematic presentation of a chromatographic system with partition of analyte A between the phases; $v$ mobile phase velocity	<b>19</b>
Figure 1.N	HPLC Instrumentation	<b>24</b>
Figure 1.O	HPLC Pump	<b>25</b>
Figure 1.P	HPLC Chromatogram	<b>28</b>

	<b>Chapter 2</b> <b>Simultaneous Analysis of Metronidazole and Diloxanide Furoate in Human Plasma (In-vivo) by LC-MS/MS method</b>	<b>60</b>
Figure 2.A	Structure of Metronidazole	61
Figure 2.B	Structure of Diloxanide Furoate	62
Figure 2.C	Standard LC chromatogram of Metronidazole and Diloxanide Furoate	80
Figure 2.D	Blank chromatogram of Metronidazole and Diloxanide Furoate	80
Figure 2.E	Standard LC chromatogram of Metronidazole	81
Figure 2.F	Standard LC chromatogram of Diloxanide Furoate	81
Figure 2.G	Mass spectrum of Metronidazole	82
Figure 2.H	Mass spectrum of Diloxanide Furoate	82
Figure 2.I	Linearity graph for Metronidazole	84
Figure 2.J	Linearity graph for Diloxanide Furoate	85
	<b>Chapter 3</b> <b>Simultaneous Analysis of Telmisartan and Hydrochlorothiazide in Human Plasma (In-vivo) by LC-MS/MS method</b>	<b>99</b>
Figure: 3.A	Structure of Telmisartan	100
Figure 3.B	Structure of Hydrochlorothiazide	102
Figure3.C	Standard LC chromatogram of Telmisartan and Hydrochlorothiazide	122
Figure 3.D	Blank chromatogram of Telmisartan and Hydrochlorothiazide	122

Figure 3.E	Standard LC chromatogram of Telmisartan	123
Figure 3.F	Standard LC chromatogram of Telmisartan	123
Figure 3.G	Mass spectrum of Telmisartan	124
Figure 3.H	Mass spectrum of Hydrochlorothiazide	124
Figure 3.I	Linearity graph for Telmisartan	126
Figure 3.J	Linearity graph for Hydrochlorothiazide	126
	<b>Chapter 4</b> <b>Simultaneous Analysis of Metformin and Glibenclamide in Human Plasma (In-vivo) LC-MS/MS method</b>	<b>142</b>
Figure 4.A	Structure of Metformin	143
Figure 4.B	Structure of Glibenclamide	145
Figure 4.C	Standard LC chromatogram of Metformin and Glibenclamide	159
Figure 4.D	Blank chromatogram of Metformin and Glibenclamide	159
Figure 4.E	Standard LC chromatogram of Metformin	160
Figure 4.F	Standard LC chromatogram of Glibenclamide	160
Figure 4.G	Mass spectrum of Metformin	161
Figure 4.H	Mass spectrum of Glibenclamide	161
Figure 4.I	Linearity graph for Metformin	163
Figure 4.J	Linearity graph for Glibenclamide	164
	<b>Chapter 5</b> <b>RP HPLC Method Development and Validation for Simultaneous Estimation of Metronidazole and Diloxanide Furoate in Formulation Dosage Forms</b>	<b>181</b>
Figure 5.A	Standard chromatogram of Metronidazole and Diloxanide Furoate	185
Figure 5.B	Formulation chromatogram of Metronidazole and Diloxanide Furoate	185

Figure 5.C	Calibration curve of Diloxanide Furoate	187
Figure 5.D	Calibration curve of Metronidazole	188
	<b>Chapter 6</b> <b>RP HPLC Method Development and Validation for Simultaneous Estimation of Telmisartan and Hydrochlorothiazide in Formulation Dosage Forms</b>	196
Figure: 6.A	Blank chromatogram	201
Figure: 6.B	Standard chromatogram	201
Figure: 6.C	Formulation chromatogram	202
Figure: 6.D	Calibration curve of Telmisartan	204
Figure 6.E	Calibration curve of Hydrochlorothiazide	205
	<b>Chapter 7</b> <b>RP HPLC Method Development and Validation for Simultaneous Estimation of Metformin and Glibenclamide in Formulation Dosage Forms</b>	213
Figure 7.A	Standard chromatogram of Metformin and Glibenclamide	217
Figure 7.B	Blank chromatogram of Metformin and Glibenclamide	217
Figure 7.C	Calibration Curve for Metformin	220
Figure 7.D	Calibration Curve for Glibenclamide	220
Figure 7.E	Formulation chromatogram of Metformin and Glibenclamide	226
	<b>Chapter 8</b> <b>Development and Validation of New Analytical Methods for the Estimation of Chemotherapeutic Drugs by using RP-HPLC: Oxaliplatin, Capecitabine, Carboplatin and Gemcitabine</b>	230
Figure 8.A	Structure of Oxaliplatin	231

Figure 8.B	Structure of Capecitabine	233
Figure 8.C	Structure of Carboplatin	235
Figure 8.D	Structure of Gemcitabine	239
Figure 8.E	Blank Chromatogram for Oxaliplatin	265
Figure 8.F	system suitable chromatogram for Oxaliplatin	265
Figure 8.G	Blank Chromatogram for Capecitabine	266
Figure 8.H	Standard chromatogram of Capecitabine	266
Figure 8.I	Blank Chromatogram for Carboplatin	267
Figure 8.J	Standard chromatogram of Carboplatin	267
Figure 8.K	Blank Chromatogram for Gemcitabine	268
Figure 8.L	Standard chromatogram of Gemcitabine	268
Figure 8.M	Linearity Graphs for the drugs in the study	271
Figure 8.N	Formulation Chromatogram for Oxaliplatin	280
Figure 8.O	Formulation Chromatogram for Capecitabine	280
Figure 8.P	Formulation chromatogram of Carboplatin	281
Figure 8.Q	Formulation chromatogram of Gemcitabine	281
	<b>Chapter 9</b> <b>Development and Validation of New Analytical Methods for the Estimation of Different Drugs by using RP-HPLC: Carvedilol, Venlafaxine, Thalidomide and Tenofovir</b>	293
Figure 9.A	structure of Carvedilol	294

---

Figure 9.B	Structure of Venlafaxine	296
Figure 9.C	Structure of Thalidomide	298
Figure 9.D	Structure of Tenofovir	300
Figure 9.E	Blank Chromatogram for Carvedilol	324
Figure 9.F	system suitable chromatogram for Carvedilol	324
Figure 9.G	Blank Chromatogram for Venlafaxine	325
Figure 9.H	system suitable chromatogram for Venlafaxine	325
Figure 9.I	Blank Chromatogram for Thalidomide	326
Figure 9.J	Standard chromatogram of Thalidomide	326
Figure 9.K	Blank Chromatogram for Tenofovir	327
Figure 9.L	Standard chromatogram of Tenofovir	327
Figure 9.M	Linearity Graphs for the proposed methods	331
Figure 9.N	Formulation chromatogram for Carvedilol	337
Figure 9.O	Formulation chromatogram for Venlafaxine	338
Figure 9.P	Formulation chromatogram for Thalidomide	338
Figure 9.Q	Formulation chromatogram for Tenofovir	339